Immunotherapy in Urological Tumors

Anand Sharma, Narin M. Suleyman, Nikhil Vasdev, Oliver Jones

Research output: Contribution to journalArticlepeer-review

2 Downloads (Pure)


The past decade has seen significant improvement in our understanding of tumor biological features, which has led to use of anti-programmed-death 1 (PD-1) and anti-PDligand-1 (PD-L1) agents and cytotoxic T lymphocytes antigen 4 (CTLA-4) inhibitors in a multitude of cancers. These immunotherapeutic agents have shown activity in melanoma, lung, head and neck, colorectal, urological, and other cancers. This article details the use of immunotherapy agents in urothelial, renal, prostate, and testicular tumors.
Original languageEnglish
Pages (from-to)15–20
Number of pages6
JournalReviews in Urology
Issue number1
Publication statusPublished - 2019


Dive into the research topics of 'Immunotherapy in Urological Tumors'. Together they form a unique fingerprint.

Cite this